Brief: Brii Biosciences Says China's NMPA Granted Approval Of Co's Monoclonal Neutralizing Antibody Therapy
08/12/2021 22:10
Dec 9 (Reuters) - Brii Biosciences Ltd 2137.HK :
* CHINA'S NMPA GRANTED APPROVAL OF CO'S MONOCLONAL
NEUTRALIZING
ANTIBODY THERAPY
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR